These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1778870)

  • 41. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum beta-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria.
    Stürenburg E; Lang M; Horstkotte MA; Laufs R; Mack D
    J Antimicrob Chemother; 2004 Nov; 54(5):870-5. PubMed ID: 15471997
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Occurrence of extended-spectrum beta-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens in Korea and investigation of screening criteria.
    Park YJ; Park SY; Oh EJ; Park JJ; Lee KY; Woo GJ; Lee K
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):265-9. PubMed ID: 15808318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In-vitro antibacterial activity of DQ-2556 and its stability to various beta-lactamases.
    Fujimoto T; Watanabe M; Inoue M; Mitsuhashi S
    J Antimicrob Chemother; 1990 Sep; 26(3):329-41. PubMed ID: 2228824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
    Wang FD; Liu IM; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. False extended-spectrum {beta}-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins.
    Beceiro A; Maharjan S; Gaulton T; Doumith M; Soares NC; Dhanji H; Warner M; Doyle M; Hickey M; Downie G; Bou G; Livermore DM; Woodford N
    J Antimicrob Chemother; 2011 Sep; 66(9):2006-10. PubMed ID: 21742679
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents.
    Bell JM; Turnidge JD;
    Pathology; 2001 Feb; 33(1):53-60. PubMed ID: 11280610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of cefepime and cefpirome compared to other third-generation cephem antibiotics against gram-negative nosocomial pathogens.
    Tumah HN
    Pharmazie; 2004 Nov; 59(11):854-8. PubMed ID: 15587586
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Antimicrobial resistance monitoring of gram-negative bacilli isolated from 15 teaching hospitals in 2014 in China].
    Wang Q; Wang H; Yu Y; Xu X; Sun Z; Lu J; Yang B; Zhang L; Hu Z; Feng X; Xu Y; Ni Y; Mei Y; Liao K; Ji P; Chu Y
    Zhonghua Nei Ke Za Zhi; 2015 Oct; 54(10):837-45. PubMed ID: 26675021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Survey of the prevalence of beta-lactamases amongst 1000 gram-negative bacilli isolated consecutively at the Royal London Hospital.
    Liu PY; Gur D; Hall LM; Livermore DM
    J Antimicrob Chemother; 1992 Oct; 30(4):429-47. PubMed ID: 1490917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of cefepime, a new parenteral cephalosporin, against recent European blood isolates and in comparison with piperacillin/tazobactam.
    Dornbusch K; Mörtsell E; Göransson E
    Chemotherapy; 1990; 36(4):259-67. PubMed ID: 2174761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
    Spencer RC
    Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Screening extended-spectrum beta-lactamase production in Enterobacter cloacae and Serratia marcescens using antibiogram-based methods.
    Su PA; Wu LT; Cheng KC; Ko WC; Chuang YC; Yu WL
    J Microbiol Immunol Infect; 2010 Feb; 43(1):26-34. PubMed ID: 20434120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods.
    Livermore DM
    Eur J Clin Microbiol; 1987 Aug; 6(4):439-45. PubMed ID: 3311738
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
    Chen MJ; Wang H;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interactions of FCE 22101 with class I beta-lactamases.
    Yang Y; Livermore DM
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():85-94. PubMed ID: 2786519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interactions of meropenem with class I chromosomal beta-lactamases.
    Yang YJ; Livermore DM
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():207-17. PubMed ID: 2808208
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activity of temocillin and other penicillins against beta-lactamase-inducible and -stably derepressed enterobacteria.
    Yang Y; Livermore DM
    J Antimicrob Chemother; 1988 Sep; 22(3):299-306. PubMed ID: 3263354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.